CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Effects of MLC601 on early vascular events in patients after stroke: The CHIMES study
Authors
Joel M. Advincula
Neil Ambasing
+39 more
Alejandro C. Baroque
Eli John Berame
Marie Germaine Bousser
Maria Teresa Canete
Bernard P L Chan
Hui Meng Chang
Siwaporn Chankrachang
Christopher L H Chen
Songkram Chotickanuchit
Carlos L. Chua
Deidre Anne De Silva
H. Asita De Silva
Gaik Bee Eow
Randolph John Fangonillo
Herminigildo H. Gan
John Harold B Hiyadan
Annabelle Y. Lao
Chun Fan Lee
Johnny Lokin
Teoh Hock Luen
Marlie Jane Mamauag
Sombat Muengtaweepongsa
Jose C. Navarro
Samart Nitinun
Shrikant Pande
Niphon Poungvarin
Udaya Ranawake
Ma Cristina San Jose
Ma Socorro Sarfati
Vijay Sharma
Rajinder Singh
Nijasri C. Suwanwela
San San Tay
Umapathi Thirugnanam
Somchai Towanabut
Narayanaswamy Venketasubramanian
Nirmala Wijekoon
K. S Lawrence Wong
Sherry H Y Young
Publication date
1 January 2013
Publisher
'Ovid Technologies (Wolters Kluwer Health)'
Doi
Cite
Abstract
BACKGROUND AND PURPOSE - Early vascular events are an important cause of morbidity and mortality in the first 3 months after a stroke. We aimed to investigate the effects of MLC601 on the occurrence of early vascular events within 3 months of stroke onset. METHODS - Post hoc analysis was performed on data from subjects included in the CHInese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES) study, a randomized, placebo-controlled, double-blinded trial that compared MLC601 with placebo in 1099 subjects with ischemic stroke of intermediate severity in the preceding 72 hours. Early vascular events were defined as a composite of recurrent stroke, acute coronary syndrome, and vascular death occurring within 3 months of stroke onset. RESULTS - The frequency of early vascular events during the 3-month follow-up was significantly less in the MLC601 group than in the placebo group (16 [2.9%] versus 31 events [5.6%]; risk difference=-2.7%; 95% confidence interval, -5.1% to -0.4%; P=0.025) without an increase in nonvascular deaths. Kaplan-Meier survival analysis showed a difference in the risk of vascular outcomes between the 2 groups as early as the first month after stroke (Log-rank P=0.024; hazard ratio, 0.51; 95% confidence interval, 0.28-0.93). CONCLUSIONS - Treatment with MLC601 was associated with reduced early vascular events among subjects in the CHIMES study. The mechanisms for this effect require further study. © 2013 American Heart Association, Inc.Link_to_subscribed_fulltex
Similar works
Full text
Available Versions
HKU Scholars Hub
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:hub.hku.hk:10722/220883
Last time updated on 01/06/2016